

CASE D0051 NP

CERTIFICATE OF MAILING

Thereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico

Type or print name

Signature

10-27-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1646

CHEN ET AL.

Examiner: MOORE, WILLIAM W

APPLICATION NO: 09/993,180 FILED: NOVEMBER 14, 2001

FOR: POLYNUCLEOTIDE ENCODING A NOVEL HUMAN SERPIN

SECRETED FROM LYMPHOID CELLS LSI-01

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date: /0-27-04

Stephen C. D'Amico Agent for Applicants Reg. No. 46,652



CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico

Type or print name

Signature

10-27-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1646

CHEN ET AL.

Examiner: MOORE, WILLIAM W

APPLICATION NO: 09/993,180 FILED: NOVEMBER 14, 2001

FOR: POLYNUCLEOTIDE ENCODING A NOVEL HUMAN SERPIN

SECRETED FROM LYMPHOID CELLS LSI-01

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

11/01/2004 MBLAMED 00000002 193880 03393160

01 FC:1898

160.00 DR

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Stephen C. D'Amico

Agent for Applicants

Reg. No. 46,652

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-5289

Date: 10-27-04

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO. D0051 NP APPLICATION NO. 09/993,180 APPLICANT CHEN ET AL. FILING DATE NOVEMBER 14, 2001

Group 1646

By The State of th		
OCI 5 8 5004 1		
	•	
Vb E		
Use several si	heets if necessary)	

& TRADEMAN			U.S. 1	PATENT DOCUMENTS	_			-
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CL	ASS SUBCLA	SS F	ILING DATE
	AA							
	AB							
	AC							
	AD							
	ΑE							
	AF							
	AG							
	АН			1				
	ΑI							
	AJ							
	AK							
	AL							
·-			FOREIG	N PATENT DOCUMENTS			•	
		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN	SLATION NO
	AM	WO0155390A1	8/2/01	PCT				
	AN	WO0214358A2	2/21/02	PCT				
	AO	WO02072769AW	9/19/02	PCT				
	AP	WO9811134	3/19/98	PCT				
	AQ	WO0200690A2	1/3/02	PCT				
		OTHER DOC	UMENTS (Including Author, Title, Date, Pertine	ent pages, E	tc.)		
	AR	Altschul, et al., "Basic Alignment Search Tool", J. Mol. Biol, Vol. 215, pp. 403-410 (1990)						
	AS	Backes, et al., "Synthe the extended substrate 193 (2000)	esis of positions of specificity	onal-scanning libraries of fluoro of plasmin and thrombin", Natu	genic pep ire Biotech	tide substrat nology, Vol.	es to de 18, pp.	efine 187-
	АТ	Balasubramanian, et al., "Active Site-Directed Synthetic Thrombin Inhibitors: Synthesis, in Vitro and in Vivo Activity Profile of BMY 44621 and Analogs. An Examination of the Role of the Amino Group in the D-Phe-Pro-Arg-H Series", J. Med. Chem., Vol. 36, pp. 300-303 (1993)						
EXAMINE	R			DATE CONSIDERED			_	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0051 NP APPLICATION NO. 09/993,180 APPLICANT CHEN ET AL. FILING DATE NOVEMBER 14, 2001

Group 1646

FOREIGN PATENT DOCUMENTS

		FOREIG	GN PATENT DOCUMENTS	i			
TATATHAN CHE	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRAN YES	SLATION NO
2AA	WO0208284A2	1/31/02	PCT				
AB						一	一
AC							
AD							
AE							<u> </u>
AF							
AG							
AH							
Al							
AJ						H	
AK							
AL							一
AM							
AN							
AO							
AP							<u> </u>
AQ							li —
AR							<u> </u>
AS							
AT							
AU							
AV							
AW							
AX							
AY							
AZ							
EXAMINER	1	l <u> </u>	DATE CONSIDERED				

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. **D0051 NP** APPLICATION NO. 09/993,180 **APPLICANT** CHEN ET AL. FILING DATE **NOVEMBER 14, 2001**

Group 1646

2 8 2004	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
& TRADEMENT 3A	Bateman, et al., "The Pfam Protein Families Database", Nucleic Acids Research, Vol. 28(1), pp. 263-266 (2000)
3A	Baumann, et al., "Crystal Structure of Cleaved Human α ₁ . Antichymotrypsin at 2.7 A Resolution and Its Comparison with Other Serpins", J. Mol. Biol., Vol. 218, pp. 595-606 (1991)
3A	Blinder, et al., "Site-directed Mutagenesis of Arginine 103 and Lysine 185 in the Proposed Glycosaminoglycan-binding Site of Herparin Cofactor II", J. Biol. Chem., Vol. 265(1), pp. 286-291 (1990)
3A	Blinder, et al., "Heparin Cofactor II _{Oslo} , Mutation of ARG-189 To His Decreases The Affinity for
3A	Bohm, Hans-Joachim, "The computer program LUDI: A new method for the de novo design of enzyme inhibitors", J. Computer-Aided Molecular Design, Vol. 6, pp. 61-78 (1992)
3A	Cajot, et al., "Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells", PNAS, Vol. 87, pp. 6939-6943 (1990)
3A	Cardozo, et al., "Homology Modeling by the ICM Method", Proteins, Vol. 23, pp. 403-414 (1995)
ЗА	Carrell, et al., "The Serpins: Evolution and Adaptation in a Family of Protease Inhibitors", Cold Spring Harbor Symposia on Quantitative Biology", Vol. LII, pp. 527-535 (1987)
3A	Carrell, et al., " α_1 - Antitrypsin and the serpins: variation and countervariation", TIBS, pp. 20-24 (1985)
3A	Chai, et al., "Molecular Cloning, Sequence Analysis, and Chromosomal Localization of the Human Protease Inhibitor 4 (Kallistatin) Gene (P14)", Genomics, Vol. 23, pp. 370-378 (1994)
3A	Chai, et al., "Kallistatin: A Novel Human Serine Proteinase Inhibitor", J. Biol. Chem., Vol. 268 (32), pp. 24498-24505 (1993)
3A	Chandra, et al., "Sequence Homology between Human "α1- Antichymotrypsin, α1-Antitrypsin, and Antithrombin III", Biochem., Vol. 22(22), pp. 5055-5061 (1983)
3A	Chen, Wen-Tien, "Membrance proteases:roles in tissue remodeling and tumour invasion", Curr. Opin. Cell Biol., Vol. 4, pp. 802-809 (1992)
3A	Clarke, et al., "Cloning of a human collagen-binding protein, and its homology with rat gp46, chick hsp47 and mouse J6 proteins", Biochemica Biophysica Acta, Vol. 1129, pp. 246-248 (1992)
EXAMINER	DATE CONSIDERED

OCT 2 9 2004

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0051 NP APPLICATION NO. 09/993,180 **APPLICANT** CHEN ET AL. **FILING DATE NOVEMBER 14, 2001**

Group 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

.5/	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
TRADE 4AA	Clark, et al., "The Secreted Protein Discovery Initiative (SPDI), a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A Bioinformatics Assessment", Genome Res., Vol. 13, pp. 2265-2270 (2003)
4AB	Combrink, et al., "1,2-Benzisothiazol-3-one 1,1-Dioxide Inhibitors of Human Mast Cell Tryptase", J. Med. Chem., Vol. 41, pp. 4854-4860 (1998)
4AC	Cooper, et al., "Phosphorylation Sites in Enolase and Lactate Dehydrogenase Utilized by Tyrosine Protein Kinases in Vivo and in Vitro", J. Biol. Chem., Vol. 259(12), pp. 7835-7841 (1984)
4AD	Dano, et al., "Plasminogen Activators, Tissue Degradation, and Cancer", Advances in Cancer Research, Vol. 44, pp. 139-266 (1985)
4AE	Feramisco, et al., "Optimal Spatial Requirements for the Location of Basic Residues in Peptide Substrates for the Cyclic AMP-dependent Protein Kinase", J. Biol. Chem., Vol. 255(9), pp. 4240-4245 (1980)
4AF	Foekens, et al., "Prognostic Value of Urokinase-type Plasminogen Activator in 671 Primary Breast Cancer Patients", Cancer Res., Vol. 52, pp. 6101-6105 (1992)
4AG	Flink, et al., "Complete amino acid sequence of human thyroxine-binding globulin deduced from cloned DNA: Close homology to the serine antiproteases", PNAC, Vol. 83, pp. 708-7712 (1986)
4AH	Forgue-Lafitte, "Effects of Ketoconazole on the Proliferation and Cell Cycle of Human Cancer Cell Lines", Cancer Res., pp. 6827-6831 (1992)
4AI	Foucre', et al., "Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malighant vs. benign breast tumours", Br. J. Cancer, Vol. 64, pp. 926-932 (1991)
4AJ	Gils, et al., "Structure-function Relationships in Serpins: Current Concepts and Controversies", Thromb. Haemost., Vol. 80, pp. 531-541 (1998)
4AK	Glass, et al., "Phosphorylation by Cyclic GMP-dependent Protein Kinase of a Synthetic Peptide Corresponding to the Autophosphorylation Site in the Enzyme", J. Biol. Chem., Vol. 258(24), pp. 14797-14803 (1983)
4AL	Glass, et al., "Synthetic Peptides Corresponding to the Site Phosphorylated in 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase as Substrates of Cyclic Nucleotide-dependent Protein Kinases", J. Biol. Chem., Vol. 261(6), pp. 2987-2993 (1986)
4AM	Goodford, P.J., "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules", J. Med. Chem., Vol. 28, pp. 849-857 (1985)
4AN	Goodsell, et al., "Automated Docketing of Substrates to Proteins by Simulated Annealing", Proteins, Vol. 8, pp. 195-202 (1990)
EXAMINER	DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0051 NP APPLICATION NO. 09/993,180 **APPLICANT** CHEN ET AL. **FILING DATE NOVEMBER 14, 2001**

Group 1646

\$	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
5A	Grand, Roger, J.A., "Acylation of viral and eukaryotic proteins", Biochem. J., Vol. 258, pp. 625-638 (1989)
5A	Heidtmann, et al., "Synthesis and Secretion of Plasminogen Activators and Plasminogen Activator Inhibitors in Cell Lines of Different Groups of Human Lung Tumors", Cancer Res., Vol. 49, pp. 6960-6965 (1989)
5A	Hendlich, et al., "Identification of Native Protein Folds Amongst a Large Number of Incorrect
5A	Hocini, et al., "Secretory Leukocyte Protease Inhibitor Inhibits Infection of Monocytes and Lymphocytes with Human Immunodeficiency Virus Type 1 but Does Not Interfere with Transcytosis of Cell-Associated Virus across Tight Epithelial Barriers", Clin. Lab. Diagnostic Lab. Immonol., Vol. 7(3), pp. 515-518 (2000)
5A	Memorec, et al., "The Prosite Database, its Status in 1999", Nucleic Acid Res., Vol. 27(1), pp. 215-219 (1999)
5A	Holland, et al., "A Major Estrogen-regulated Protein Secreted from the Liver of Xenopus laevis is a Member of the Serpin Superfamily", J. Biol. Chem., Vol. 267(10), pp. 7053-7059 (1992)
5A	Huber, et al., "Implications of the Three-Dimensional Structure of α ₁ -Antitrypsin for Structure and Function of Serpins", Biochem., Vol. 28(23), pp. 8951-8966 (1989)
5A	Hunter, Tony, "Synthetic Peptide Substrates for a Tyrosine Protein Kinase", J. Biol. Chem., Vol. 257(9), pp. 4843-4848 (1982)
5A	Huntington, et al., "Structure of a serpin-protease complex shows inhibition by deformation", Nature, Vol. 407, pp. 923-926 (2000)
5A	Janicke, et al., "Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer", Breast Cancer Res. Treatment, Vol. 24, pp. 195-208 (1993)
5A	Kalaria, et al., "Molecular Aspects of Inflammatory and Immune Responses in Alzheimer's Disease", Neurobiology of Aging, Vol. 17(5), pp. 687-693 (1996)
5A	Kam, et al., "Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors", Biochimica Biophysica Acta, Vol. 1477, pp. 307-323 (2000)
5A	Kishimoto, et al., "Studies on the Phosphorylation of Myelin Basic Protein by Protein Kinase C and Adenosine 3':5'-Monophosphate-dependent Protein Kinase", J. Biol. Chem., Vol. 260(23), pp. 12492-12499 (1985)
5A	Komiyama, et al., "Inhibition of Interleukin-1β Converting Enzyme by the Cowpox Virus Serpin
EXAMINER	DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0051 NP APPLICATION NO. 09/993,180 APPLICANT CHEN ET AL. FILING DATE NOVEMBER 14, 2001

Group 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

A S		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
& TRADENT	6AA	Kreil, Gunther, "Occurrence, Detection, and Biosynthesis of Carboxy-Terminal Amides", Methods Enzymology, Vol. 106, pp. 218-223 (1984)
	6AB	Kuntz, et al., "A Geometric Approach to Macromolecule-Ligand Interactions", J. Mol. Biol., Vol. 161, pp. 269-288 (1982)
	6AC	Lane, et al., "Antithrombin and its deficiency states", Blood Coagulation Fibrinolysis, Vol. 3, pp. 315-341 (1992)
	6AD	Lindmark, et al., "The microheterogeneity of desialylated α ₁ -antichymotrypsis: the occurrence of two amino-terminal isoforms, one lacking a His-Pro dipeptide", Biochimica Biophysica Acta, Vol. 997, pp. 90-95 (1989)
	6AE	Lukacs, et al., "Arginine substitutions in the hinge region of antichymotrypsin affect serpin β-sheet rearrangement", Nature, Vol. 3(10), pp. 888-893 (1996)
	6AF	Lukacs, et al., "Engineering an Anion-Binding Cavity in Antichymotrypsin Modulates the 'Spring-Loaded' Serpin-Protease Interaction", Biochem., Vol. 37, pp. 3297-3304 (1998)
	6AG	Martin, et al., "Calphotin: A Drosophila photoreceptor cell calcium-binding protein", PNAS, Vol. 90, pp. 1531-1535 (1993)
	6AH	Meissauer, et al., "Urokinase-Type and Tissue-Type Plasminogen Activators Are Essential for in Vitro Invasion of Human Melanoma Cells", Vol. 192, pp. 453-459 (1991)
. "	6AI	Miller, Andrew, "The European Synchrotron Radiation Facility and Angiography", Curr. Op. Struct. Biol., Vol. 2, pp. 242-247 (1992)
	6AJ	Ngan, et al., "Expression in Non-Hodgkin's Lymphoma of the bcl-2 Protein Associated with the t(14;18) Chromosomal Translocation", New England J. Med., Vol. 318(25), pp. 1638-1644 (1988)
	6AK	Nguyen, et al., "The Specific Variable Domain of Camel Heavy-chain Antibodies is Encoded in the Germline", J. Mol. Biol., Vol. 275, pp. 413-418 (1998)
	6AL	Martin, Yvonne, C., "3D Database Searching in Drug Design", J. Med. Chem., Vol. 35(12), pp. 2145-2154 (1992)
	6AM	Morii, et al., "Amino Acid Sequence at the Reactive Site of Human α_1 -Antichymotrypsin", J. of Biol. Chem., Vol. 258(21), pp. 12749-12752 (1983)
	6AN	Novotny, et al., "Criteria That Discriminate Between Native Proteins and Incorrectly Folded Models", Proteins, Vol. 4, pp. 19-30 (1988)
EXAMINE	R	DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(se several sheets if necessary

ATTY. DOCKET NO. **D0051 NP APPLICATION NO.** 09/993,180 **APPLICANT** CHEN ET AL. **FILING DATE NOVEMBER 14, 2001**

Group 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

ZA TO A DEMARE	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)				
	7AA	Opal, Steven, M., "Therapeutic rational pp. S34-S37 (2000)	ale for antithrombin III in sepsis", Crit. Care Med., Vol. 28(9),		
	7AB	O'Reilly, et al., "Antiangiogenic Activit Science, Vol. 285, pp. 1926-1928 (19	y of the Cleaved Conformation of the Serpin Antithrobin", 99)		
	7AC		ctive Tissue by Human Carcinoma Cell Lines: Requirement and Interstitial Collagenase", Cancer Res., Vol. 52, pp. 6754-		
	7AD	Osterwalder, et al., "Neuroserpin, an a 15(12), pp. 2944-2953 (1996)	axonally secreted serine protease inhibitor", EMBO J., Vol.		
	7AE	Pan, et al., "Two Newly Characterized GCET2, Have Differential Expression 163(1), pp. 135-144 (2003)	Germinal Center B-Cell-Associated Genes, GCET1 and in Normal and Neoplastic B Cells", Amer. J. Path., Vol.		
	7AF	Patschinsky, et al., "Analysis of the se phosphorylation", PNAS, Vol. 79, pp.	equence of amino acids surrounding sites of tyrosine 973-977 (1982)		
	7AG	Pearson, William, R., "Rapid and Sen Methods Enzymology, Vol. 183, pp. 6	sitive Sequence Comparison with FASTP and FASTA", 3-98 (1990)		
	7AH		yte Proliferation by Uterine Serpin: Interleukin-2 mRNA sponsiveness to Interleukin-2", Vol. 223, pp. 75-81 (2000)		
	7AI	Pinna, Lorenzo, A., "Casein kinase 2: Biophysica Acta, Vol. 1054, pp. 267-2	an 'eminence grise' in cellular regulation?", Biochimica 84 (1990)		
	7AJ		bstitution Causes a Defective α^1 -Antichymotrypsin Allele ung Disease", Genomics, Vol. 17, pp. 740-743 (1993)		
	7AK	Pratt, et al., "Antithrombin: Structure a (1991)	and Function", Seminars in Hematology, Vol. 28(1), pp. 3-9		
	7AL	Ragg, et al., "Glycosaminoglycan-mediated Leuserpin-2/Thrombin Interaction", J. Biol. Chem., Vol. 265(36), pp. 22386-22391 (1990)			
	7AM	Reed, et al., "Synergistic fibrinolysis: 0 that inhibits α_2 -antiplasmin", PNAS, V	Combined effects of plasminogen activators and an antibody ol. 87, pp. 1114-1118 (1990)		
	7AN	Reilly, et al., "Type-1 Plasminogen Activator Inhibitor in Human Breast Carcinomas", Int. J. Cancer Vol. 50, pp. 208-214 (1992)			
EXAMINE	₹		DATE CONSIDERED		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0051 NP APPLICATION NO. 09/993,180 APPLICANT CHEN ET AL. FILING DATE NOVEMBER 14, 2001

Group 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

. ~	<i>§</i> /	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
TRADENTA	8AA	Remold-O'Donnell, Eileen, "The ovalbumin family of serpin proteins", FEBS, Vol. 315(2), pp. 105-108 (1993)
	8AB	Rubin, et al., "Cloning, Expression, Purification, and Biological Activity of Recombinant Native and Variant Human α1-Antichymotrypsins", J. Biol. Chem., Vol. 265(2), pp. 1199-1207 (1990)
	8AC	Saitou, et al., "Identification of the TCL6 genes within the breakpoint cluster region on chromosome 14q32 in T-cell leukemia", Oncogene, Vol. 19, pp. 2796-2802 (2000)
1-	8AD	Sali, et al., "Evaluation of Comparative Protein Modeling by Modeller", Proteins, Vol. 23, pp. 318-326 (1995)
	8AE	Shirasuna, et al., "Extracellular Matrix Production and Degradation by Adenoid Cystic Carcinoma Cells: Participation of Plasminogen Activator and Its Inhibitor in Matrix Degradation", Cancer Res., Vol. 53, pp. 147-152 (1993)
	8AF	Shirk, et al., "Role of the H Helix in Heparin Binding to Protein C Inhibitor", J. Biol. Chem., Vol. 269(46), pp. 28690-28695 (1994)
	8AG	Sumiyoshi, et al., "Plasminogen Activator System in Human Breast Cancer", Int. J. Cancer, Vol. 50, pp. 345-348 (1992)
	8AH	Sumiyoshi, et al., "Increase in Levels of Plasminogen Activator and Type-1 Plasminogen Activator Inhibitor in Human Breast Cancer: Possible roles in tumor progression and metastasis", Thromb. Res., Vol. 63, pp. 59-71 (1991)
	8AI	Testa, et al., "The role of urokinase-type plasminogen activator in aggressive tumor cell behavior", Cancer Metastasis Reviews, Vol. 9, pp. 353-367 (1990)
	8AJ	Towler, et al., "The Biology and Enzymology of Eukaryotic Protein Acylation", Ann Rev. Biochem., Vol. 57, pp. 69-99 (1988)
	8AK	Tsuda, et al., "Detection of a new mutant α -1-antichymotrypsin in patients with occlusive-cerebrovascular disease", FEBS, Vol. 304(1), pp. 66-68 (1992)
	8AL	Whinna, et al., "Role of Lysine 173 in Heparin Binding to Heparin Cofactor II", J. Biol. Chem., Vol. 266(13), pp. 8129-8135 (1991)
	8AM	Whisstock, et al., "An atlas of serpin conformations", TIBS, Vol. 23, pp. 63-67 (1998)
	8AN	Woodgett, et al., "Substrate specificity of protein kinase C", J. Biochem., Vol. 161, pp. 177-184 (1986)
EXAMINE	R	DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0051 NP APPLICATION NO. 09/993,180 APPLICANT CHEN ET AL. FILING DATE NOVEMBER 14, 2001

Group 1646

A SEPTIMENT	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
TRAUS 9A	Zou, et al., "Maspin, a Serpin with Tumor-Suppressing Activity in Human Mammary Epithelial Cells", Science, Vol. 263, pp. 526-529 (1994)
9.4	NCBI Entrez Accession No. AL132708 (gi:7009592), Heilig, et al., May 4, 2001 B
94	NCBI Entrez Accession No. AL132990 (gi:15796543), Heilig, et al., September 26, 2001
94	NCBI Entrez Accession No. CAA45509 (gi:37142), Akbari, et al., June 26, 1997
94	NCBI Entrez Accession No. CAD29031 (gi:19701015), Edmonds, et al., March 23, 2002
94	NCBI Entrez Accession No. NM_175739 (gi:31343337, Namciu, et al., September 3, 2004
9,4	NCBI Entrez Accession No. NP_000345 (gi:4507377), Grasberger, et al., August 23, 2004
9,4	NCBI Entrez Accession No. NP_006206 (gi:5453888), Chai, et al., November 3, 2000
9.4	NCBI Entrez Accession No. NP_783866 (gi:28376637), Namciu, et al., September 3, 2004
9,4	NCBI Entrez Accession No. P01011 (gi:112874), Chandra, et al., October 25, 2004
9,4	NCBI Entrez Accession No. 1QLPA (gi:6137432), Elliott, et al., September 10, 1999
AL	
AN	1
AN	
XAMINER	DATE CONSIDERED

EXAMINER

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.